Ondansetron Orally Disintegrating Tablets

The Defense Logistics Agency is preparing to issue a national requirements contract for the supply of Ondansetron Orally Disintegrating Tablets (ODT), with specific doses of 4 MG in 30-count bottles and 8 MG in both 10- and 30-count bottles. This contract will be an unrestricted, fully competitive acquisition open to all qualified vendors, and will be executed as a firm-fixed price, requirements-type contract with a one-year base period and four optional one-year extensions. It is intended to provide a national supply source for these tablets to various federal agencies, including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and the Bureau of Prisons, through established prime vendor programs. Procurement will follow FAR Part 12 for commercial items, and estimated annual usage data will be detailed within the solicitation’s Schedule of Supplies. The solicitation is projected to be released in September 2025, though this timeline is subject to change at the agency’s discretion. All interested parties are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates and should register for alerts regarding the solicitation. The Ondansetron HCL Tablets will be procured through a separate acquisition. The main point of contact for this contract is Nancy Fernandez at DLA Troop Support in Philadelphia, with Catherine Gilbert as an additional contact.